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Central venous access devices (CVADs) risk central line-associated
bloodstream infection (CLABSI) which increase costs, morbidity and
mortality.1 The intraluminal infection source can be minimized by
needleless connector (NC) decontamination prior to each use usingchlorhexidine gluconate (CHG), povidone-iodine, or 70% isopropyl
alcohol (IPA).1 The optimal antiseptic is unknown, although povi-
done-iodine’s slow dry-time presents challenges in clinical practice.2
Combination CHG/IPA wipes,3,4 or IPA in a cap format5,6 may be supe-
rior to traditional intermittent 70% IPA wipes, but no randomized
controlled trials (RCTs) have been completed. Our aim was to
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in 70% IPA wipes, and 70% IPA caps.
MATERIALS ANDMETHODS
Setting and study design
Three-arm pilot RCT at the Royal Brisbane and Women’s Hospital
and Gold Coast University Hospital in Australia. We had University
and Hospital Ethics Committees approval (2016/410; HREC/15/
QRBW/553) and Australian New Zealand Clinical Trials Registry regis-
tration: 12615001120561. The 4-week intervention had follow-up
until 48 hours post study completion, hospital discharge or device
removal. We surveyed registered nurses (RNs) for protocol compli-
ance and satisfaction.
Participants and sample size
Eligibility criteria: ≥18 years of age; CVAD (peripherally inserted
central catheter or tunneled, cuffed CVAD) inserted <24 hours;
CVAD required for ≥7 days; and written consent. Exclusions: base-
line bloodstream infection, non-English speaking without inter-
preter, or previous enrolment. Research nurses (ReNs) screened
daily, gave trial information, and obtained consent. The target was
60 per group (1 CVAD per patient) with recruitment July 31, 2017 to
April 5, 2019.7
Randomization and blinding
Centralized, computer-generated randomization (https://random
isation.griffith.edu.au) using randomly varying permuted blocks of 3
and 6 (1:1:1 ratio): (1) 70% IPA wipes, (2) 2% CHG in 70% IPA wipes,
or (3) 70% IPA caps. Clinical outcome assessors and data analysts
were masked.
Interventions
 Seventy percent IPA wipes: 0.6 mL Alcohol Prep Pads (Reynard,
New Zealand) applied vigorously to NC for 5 seconds (manufac-
turer recommended and hospital policy), visibly dry prior to CVAD
access;
 Two percent CHG in 70% IPA wipes: 0.6 mL Alcohol and CHG Prep
Pads (Reynard, New Zealand), applied vigorously to NC for 15 sec-
onds (guideline recommendation8), visibly dry prior to CVAD
access;
 Seventy percent IPA cap: Luer access valve cap Swabcap (intensive
care unit [ICU] Medical, San Clemente) screwed onto NCs for mini-
mum 5 minutes (manufacturer-recommended) prior to each
access (70% IPA wipes were also used), then replaced with a new
cap.
NCs were Smartsite Needle-Free Valve or Max Plus (both Carefu-
sion/BD, San Diego), attached to the CVAD hubs and all entry points
of infusion systems.
ReNs provided education (clinical staff undertook the interven-
tion) and visited twice weekly to collect data, supply products, and
reinforce the protocol. Decisions to culture blood/CVAD tips, or
remove CVADs were made by medical staff (not investigators).
Primary outcome(s)
Protocol feasibility was assessed as: (1) eligibility, (2) retention
and attrition, (3) protocol adherence, (4) missing data, and (5) RN sat-
isfaction.
Secondary outcome(s)(i) CLABSI9 (2018 National Health and Safety Network definition)
assessed by masked infectious diseases specialist;
(ii) Mortality (all-cause) during trial;
(iii) Primary bloodstream infection (laboratory confirmed bloodstream
infection)9;
(iv) CVAD (tip) colonization (≥15 colony-forming units, semi-quantita-
tive culture).1
Adverse events
We captured all potentially intervention-related events, and all-
cause ICU admission (serious adverse event).
Statistical analysis
Research Electronic Data Capture (REDCap, Nashville, TN) and
Stata 15 (College Station, TX) were used. Feasibility outcomes were
analyzed against predetermined criteria (>80% of screened patients
eligible and >80% eligible patients recruited; ≥95% retention and
attrition (not withdrawn/lost to follow-up); >90% study visits with
correct products in use, and self-reported RN adherence to applica-
tion/dry times; 5% missing data (CLABSI endpoint); RN satisfaction on
1-10 numerical rating scale.
Clinical outcomes were compared using Fisher’s exact and log-
rank tests, incidence rates and Kaplan-Meier survival estimates (P <
.05 statistically significant; patients censored at discharge). A modi-
fied intention-to-treat analysis excluded only randomized patients
who never received a CVAD.
RESULTS
Patient/device characteristics are presented in Table 1 and
Supplementary Table 1. Average CVAD dwell-times were 11.3, 9.3,
and 7.4 days in the 70% IPA, 2% CHG in 70% IPA, and 70% IPA cap
groups, respectively.
Primary outcomes
Seventy percent (211/303) of screened patients were eligible and
85% (180/211) were randomized (31 declined, missed, or had CHG
allergy; Fig 1). Two patients were excluded postrandomization due
to CVAD insertion failure. There was 100% retention, 0% attrition,
and 0% missing CLABSI endpoints (Fig 1). Thus, 178 patients were
analyzed.
Observed protocol adherence was 98% (174/178); all but three 2%
CHG in 70% IPA wipe and two 70% IPA cap patients commenced the
correct intervention. 70% IPA wipe patients had no protocol devia-
tions. At least one incorrect product use occurred in 5% (3/58) 2%
CHG in 70% IPA, and 10% (6/59) 70% IPA cap patients.
Of 35 RNs (40 surveyed, response rate 88%), protocol-adherent
scrub times were reported by 31 (89%) for 70% IPA wipe, and 26
(74%) for 2% CHG in 70% IPA wipe. Median satisfaction was 9 (inter-
quartile range: 2), 10 (2), and 9 (2) for 70% IPA wipes, 2% CHG in 70%
IPA wipes, and 70% IPA caps, respectively (N = 22 for 70% IPA caps;
not all RNs had used these).
Secondary outcomes
CLABSI occurred in 1/61 (2%) 70% IPA wipe, 0/58 (0%) 2% CHG in
70% IPA wipe, and 1/59 (2%) 70% IPA cap patients (P = 1.0, Fig 2).
CLABSI incidence per 1,000 catheter-days was 1.38 (95% confidence
interval [CI]: 0.19-9.81), nil (no outcomes), and 1.70 (95% CI:
Table 1
Participant (N = 180) and device (N = 178) characteristics at baseline
70% IPA 2% CHG in 70% IPA 70% IPA cap Total
Participants per study groups* 61 (34) 59 (33) 60 (33) 180 (100)
Age (years)y 61 (50-67) 60 (47-67) 63 (50-72) 61 (50-70)
Sex: male 31 (51) 28 (47) 37 (62) 96 (53)
Cancer treatmentz 19 (31) 18 (31) 17 (28) 54 (30)
Admission type
- surgical 47 (77) 46 (78) 49 (82) 142 (79)
- haematology 12 (20) 10 (17) 10 (17) 32 (18)
- medical 1 (2) 3 (5) 1 (2) 5 (3)
- medical oncology 1 (2) 0 (0) 0 (0) 1 (1)
Comorbidities
- nil or one 17 (28) 17 (29) 16 (27) 50 (28)
- two or three 20 (33) 16 (27) 20 (33) 56 (31)
- four or more 24 (39) 26 (44) 24 (40) 74 (41)
Leucocytesx <500/ml (n=179) 5 (8) 5 (9) 5 (8) 15 (8)
Pre-existing infection 27 (44) 32 (54) 34 (57) 93 (52)
Devices by study groups* 61 (34) 58 (33) 59 (33) 178 (100)
Device type
- PICC 57 (93) 54 (93) 56 (95) 167 (94)
- TC 4 (7) 4 (7) 3 (5) 11 (6)
No. of lumens
- one 16 (26) 21 (36) 20 (34) 57 (32)
- two 45 (74) 37 (64) 39 (66) 121 (68)
Location
- upper arm 57 (93) 54 (93) 56 (95) 167 (94)
- chest 4 (7) 4 (7) 3 (5) 11 (6)
IV medications
- antibiotics 43 (70) 39 (67) 42 (71) 124 (75)
- fluids 24 (39) 25 (43) 21 (36) 70 (39)
- blood product 9 (15) 13 (22) 5 (8) 27 (15)
- antiemetic 9 (15) 7 (12) 9 (15) 25 (14)
- parenteral nutrition 12 (20) 6 (10) 6 (10) 24 (13)
- potassium chloride 6 (10) 6 (10) 4 (7) 16 (9)
- chemotherapy 4 (7) 5 (9) 5 (8) 14 (8)
- antifungal/antiviral 4 (7) 1 (2) 2 (3) 7 (4)
- other medication 29 (48) 25 (43) 17 (29) 71 (40)
No medications (fluids only) 5 (8) 6 (10) 7 (12) 18 (10)
Frequencies and column percentages shown unless otherwise noted.
*Row percentage shown.
yMedian and interquartile range (25th and 75th percentiles) shown.
zIn previous 6 months.
xAbsolute, within 72 hours of trial entry.
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caps, respectively (P = .637).
Primary bloodstream infections occurred in 2/61 (3%) 70% IPA
wipe, 2/58 (3%) CHG in 70% IPA wipe (1 of these was a mucosal bar-
rier infection), and 1/59 (2%) 70% IPA cap patients. There were no
deaths and no positive catheter tips (N = 10 cultured).
Adverse events
Two 70% IPA cap NCs became opaque (IPA appeared to seep
between the rubber inner and outer plastic, denaturing the plastic
but with no effect on patients). Four patients required transfer to ICU
for unrelated reasons (n = 3, 70% IPA wipe; n = 1, 70% IPA cap).
DISCUSSION
NC decontamination is a high-volume, high-value practice that
urgently needs high-quality evidence to prevent CLABSI. This pilot
RCT confirms the feasibility of large RCTs, with acceptable recruit-
ment, protocol adherence, and RN satisfaction, as well as high reten-
tion, low attrition and no missing data. Eligibility at 70% could be
improved with amplified research nurse availability at device inser-
tion to promote recruitment.
CLABSI incidence was low in both groups using 70% IPA, and 0
when this antiseptic was combined with CHG. These results areconsistent with laboratory data,3 and a large RCT on pre-CVAD inser-
tion skin decontamination which both favored combination CHG and
IPA10; a larger RCT would be needed to substantiate these findings in
NCs. Although scrub times differed (15 seconds for 2% CHG in 70% IPA
wipe as per guidelines,8 and 5 seconds for 70% IPA wipes as per man-
ufacturers and hospital policy), recent data indicates no difference in
effectiveness with 5, 10, or 15 second scrub times.4
CLABSI was infrequent, however as >50% were patients were dis-
charged during follow-up, future RCTs should study the entire CVAD
dwell (including home care) to ensure adequate sample size to test
hypotheses and generalizability. Nevertheless, our CLABSI of approxi-
mately 1 per 1,000 catheter-days, is similar to reported USA rates,
but may not be generalizable where rates are higher.11 Despite low
frequency, CLABSI remains the most appropriate outcome to assess
NC disinfection efficacy. Other methods such as routine CVAD tip cul-
ture have poor positive predictive value.12
Insertion bundles have reduced CLABSI, with focus now needed
on techniques to prevent postinsertion, intraluminal bacterial entry.
Currently, 70% IPA wipes are dominant due to low cost, availability
and rapid drying2 however the addition of CHG likely increases effi-
cacy,3,4 and nonrandomized studies support 70% IPA caps.5,6 Pilot
RCTs are not designed to test statistical differences in outcomes or for
the effect of potential confounders or covariates such as NC/device
type or patient factors. Large RCTs are needed to examine various
modes and strengths of antiseptics, NC materials/designs, and
Fig 2. Kaplan-Meier survival estimates for central line-associated bloodstream infection by study group. CHG, chlorhexidine gluconate; IPA, isopropyl alcohol.
Fig 1. CONSORT flowchart. CHG, chlorhexidine gluconate; CVAD, central venous access device; IPA, isopropyl alcohol;mITT, modified intention-to-treat.
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